Exosome Skincare Manufacturer Briefs Hinge on Claims, Not Vesicles
Brands briefing an exosome skincare manufacturer this quarter are asking the wrong first question. The ingredient is not what decides whether a product is lawful to sell; the sentences around it are. FDA has said since December 2019 that there are no exosome products approved by the agency, and the warning letters it has issued since have turned on what a company wrote on its website rather than what was in the bottle.
Two items make the point current. On November 20, 2026, Healio reported a case presented at the American Society for Dermatologic Surgery annual meeting in San Diego: a 54-year-old patient developed firm, itchy papules at facial injection sites weeks after receiving exosome injections at an unlicensed facility, from a product whose source she could not identify. A month earlier, on October 13, 2026, FDA’s biologics center sent a warning letter to an IV practice selling exosome and umbilical-cord-derived products, citing its website copy as evidence that the products were unapproved new drugs and unlicensed biological products.
What FDA has actually said about exosomes
FDA’s public safety notification, issued December 6, 2019 after reports of serious adverse events in Nebraska patients, states that there are currently no exosome products approved by the agency, and that exosomes used to treat diseases and conditions in people are regulated as drugs and biological products subject to premarket review and approval. That notification is about treatments. It is not a statement that a topical cosmetic containing an exosome-derived ingredient is unlawful.
The dividing line is intended use. Under the FD&C Act, a cosmetic is a product applied to the body for cleansing, beautifying, promoting attractiveness or altering the appearance. A drug is a product intended to diagnose, cure, mitigate, treat or prevent disease, or to affect the structure or any function of the body. FDA’s own guidance on whether a product is a cosmetic, a drug, or both says intended use is established by claims in labeling, advertising, on the internet or in other promotional material, and lists “regenerate cells” and “restore hair growth” among the claims that make a product a drug. The same page notes that “cosmeceutical” has no meaning under the law.
The enforcement record is a record of marketing copy
Read the letters in sequence and a pattern appears. In September 2023, a Florida manufacturer told FDA investigators during an inspection that its exosome products were for cosmetic use. FDA pointed to labeling collected at the facility that described an indication for skin damage after cosmetic or other facial injury, and concluded the products were still drugs and biological products. Saying “cosmetic” did not make it one. FDA closed that matter out on June 12, 2026, after the firm represented that it had stopped making, selling and distributing the products.
In May 2025, a Houston seller carried a disclaimer that its exosome products were for research and investigational purposes. FDA quoted the site’s aesthetic claims about skin texture, wrinkles and hair growth and classified the products as unapproved new drugs anyway. In the October 2026 letter, hedged verbs such as “supports” and “may aid” did not change the outcome either.
What this changes in a cosmetic brief
None of that stops a brand from launching a topical cosmetic formulated with an exosome-derived ingredient. It does mean the claim set has to be written before the formula is locked, because the claim is the regulatory decision and the formula is not. Three questions settle most of it: what is the ingredient by its INCI name, what does the supplier’s documentation actually support, and what will the finished pack, the product page and the paid ads say.
The third is where brands get caught, because it is the part a brand often hands to someone else. FDA reads advertising and social posts as labeling. The Federal Trade Commission separately requires advertising claims to be substantiated, and FDA does not pre-approve cosmetic claims at all, which means nobody checks the copy before it goes live. The first review may be a warning letter.
- Write the claim set first, then formulate to it. Reversing the order is how a cosmetic project becomes a drug project.
- Ask for the INCI name and the raw-material specification and certificate of analysis before approving artwork, not after.
- Keep clinic vocabulary out of retail copy. Injectable and post-procedure language does not transfer to a product applied to intact skin.
- Audit the channels you do not write yourself: affiliate scripts, influencer briefs and marketplace A+ copy are all read as intended use.
- Treat a “for research purposes” or “supports” hedge as decoration. The enforcement record shows neither one works.
What a manufacturer can and cannot settle for you
A contract manufacturer can formulate, fill and label a cosmetic, and it can hand over the supplier documents that tell you what the material is. It cannot make a drug claim lawful, and it is not the party FDA writes to about your marketing. Moe’s Group runs an FDA-registered facility in Chatsworth, California, holds ISO 22716 cosmetics GMP, ISO 9001 and ISO 45001 certificates that are downloadable in full, and formulates exosome cosmetics under white label from 200 units or custom formulation from 1,000. Registration is not approval, and no manufacturer’s certificate substantiates a sentence on your label.
Brands working on an exosome line, or deciding whether the category fits their claim appetite at all, can bring the brief to our exosome manufacturing team through the product inquiry form.
Moe’s Group Newsroom